Nat Med. 2020 Sep 7.
doi: 10.1038/s41591-020-1033-y. Online ahead of print.
Sarah Killcoyne 1 2 , Eleanor Gregson 1 , David C Wedge 3 4 5 , Dan J Woodcock 3 , Matthew D Eldridge 6 , Rachel de la Rue 7 , Ahmad Miremadi 7 , Sujath Abbas 1 , Adrienn Blasko 1 , Cassandra Kosmidou 1 , Wladyslaw Januszewicz 1 , Aikaterini Varanou Jenkins 1 , Moritz Gerstung 8 9 , Rebecca C Fitzgerald 10
PMID: 32895572 DOI: 10.1038/s41591-020-1033-y
Recent studies show that aneuploidy and driver gene mutations precede cancer diagnosis by many years1-4. We assess whether these genomic signals can be used for early detection and pre-emptive cancer treatment using the neoplastic precursor lesion Barrett's esophagus as an exemplar5. Shallow whole-genome sequencing of 777 biopsies, sampled from 88 patients in Barrett's esophagus surveillance over a period of up to 15 years, shows that genomic signals can distinguish progressive from stable disease even 10 years before histopathological transformation. These findings are validated on two independent cohorts of 76 and 248 patients. These methods are low-cost and applicable to standard clinical biopsy samples. Compared with current management guidelines based on histopathology and clinical presentation, genomic classification enables earlier treatment for high-risk patients as well as reduction of unnecessary treatment and monitoring for patients who are unlikely to develop cancer.